Abstract: A display device includes a plurality of sub-pixels. The sub-pixels include a first sub-pixel and a second sub-pixel. The first sub-pixel includes a first light emitting element and a first control circuit. The first control circuit is configured to provide a first driving current to the first light emitting element. The second sub-pixel includes a second light emitting element and a second control circuit. The second control circuit is configured to provide a second driving current to the second light emitting element. The first control circuit and the second control circuit are configured to differently control pulse amplitude of the first driving current and pulse amplitude of the second driving current, such that both of the first light emitting element and the second light emitting element emit at a target wavelength or a color point range (e.g. +/?1.5˜2 nm).

Abstract: A light-emitting device comprises a substrate; a first light-emitting unit and a second light-emitting unit formed on the substrate, each of the first light-emitting unit and the second light-emitting unit comprises a first semiconductor layer, a second semiconductor layer, and an active layer between the first semiconductor layer and the second semiconductor layer, wherein the first light-emitting unit comprises a first semiconductor mesa and a first surrounding part surrounding the first semiconductor mesa, and the second light-emitting unit comprises a second semiconductor mesa and a second surrounding part surrounding the second semiconductor mesa; a trench formed between the first light-emitting unit and the second light-emitting unit and exposing the substrate; a first insulating layer comprising a first opening on the first surrounding part and a second opening on the second semiconductor layer of the second light-emitting unit; and a connecting electrode comprising a first connecting part on the first

Abstract: An acute kidney injury predicting system and a method thereof are proposed. A processor reads the data to be tested, the detection data, the machine learning algorithm and the risk probability comparison table from a main memory. The processor trains the detection data according to the machine learning algorithm to generate an acute kidney injury prediction model, and inputs the data to be tested into the acute kidney injury prediction model to generate an acute kidney injury characteristic risk probability and a data sequence table. The data sequence table lists the data to be tested in sequence according to a proportion of each of the data to be tested in the acute kidney injury characteristics. The processor selects one of the medical treatment data from the risk probability comparison table according to the acute kidney injury characteristic risk probability.

Abstract: The invention relates to a method for judging risk of suffering kidney cancer. The method includes detecting a PSMB9 protein concentration value from a test sample. And a risk factor value is obtained after processing the PSMB9 protein concentration value with an age. When the score of the risk factor value is greater than a defined threshold value of the risk factor threshold value, then the test sample is classified as a high risk sample of a of potential kidney cancer patient.

Abstract: A 3-D path detection system includes an image capture device, a radar device and a computing module. The image capture device is provided to produce a dynamic image for calculating the x- and y-direction (transverse) pixel-value displacements according to a captured moving object image. The radar device is configured to transmit an input wireless signal to a moving object and receive a reflection signal from the moving object, and is configured to calculate a z-direction (longitudinal) displacement of the moving object according to a Doppler shift in the reflection signal. The computing module is configured to construct a 3-D path of the moving object according to the x- and y-direction pixel-value displacements of the moving object image and the z-direction displacement of the moving object.

Abstract: A reduced graphene oxide-based biosensor includes a nano-structure field-effect transistor including a channel region which includes a reduced graphene oxide having a linking moiety to be bonded to a receptor specific to an analyte, and which is represented by a formula of —(C?O)—X—COOH, wherein X represents a C1-C3 alkenylene group or a C1-C3 alkylene group.

Abstract: A 3-D path detection system includes an image capture device, a radar device and a computing module. The image capture device is provided to produce a dynamic image for calculating the x- and y-direction (transverse) pixel-value displacements according to a captured moving object image. The radar device is configured to transmit an input wireless signal to a moving object and receive a reflection signal from the moving object, and is configured to calculate a z-direction (longitudinal) displacement of the moving object according to a Doppler shift in the reflection signal. The computing module is configured to construct a 3-D path of the moving object according to the x- and y-direction pixel-value displacements of the moving object image and the z-direction displacement of the moving object.

Abstract: A reduced graphene oxide-based biosensor includes a nano-structure field-effect transistor including a channel region which includes a reduced graphene oxide having a linking moiety to be bonded to a receptor specific to an analyte, and which is represented by a formula of —(C?O)—X—COOH, wherein X represents a C1-C3 alkenylene group or a C1-C3 alkylene group.

Abstract: A urinary biomarker for urinary tract cancers and applications of the same are revealed. TACSTD2 is used as a non-invasive urinary biomarker for urinary tract cancers due to a feature that the TACSTD2 protein is increased significantly in urine of patients with urinary tract cancers. The quantitative urinary biomarker shows high specificity and high sensitivity for urinary tract cancer detection. Besides increasing screening efficiency, early diagnosis and early treatment of urinary tract cancers, the biomarker can also be used to assess malignancy of urinary tract cancers and monitor tumor progression for determining optimal treatment against the disease and improving the treatment results.

Abstract: A bladder cancer biomarker and a test method using the same are provided. The biomarker contains serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.

Abstract: The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.